Hairy cell leukemia

Indication for Interferon, alfa-2b

Population group: Suitable for both men and women, only adults (18 - 65 years old)

For this indication, competent medicine agencies globally authorize below treatments:

2 million IU/m² once every other day

Route of admnistration


Defined daily dose

2,000,000 - 2,000,000 [iU] per m² of body surface area (BSA)

Dosage regimen

From 2,000,000 To 2,000,000 [iU] per m² of body surface area (BSA) once every 2 day(s)

Detailed description

The recommended dose is 2 million IU/m² administered subcutaneously three times a week (every other day) for both splenectomised and non-splenectomised patients. For most patients with hairy cell leukaemia, normalisation of one or more haematological variables occurs within one to two months of interferon alpha-2b treatment. Improvement in all three haematological variables (granulocyte count, platelet count and haemoglobin level) may require six months or more. This regimen must be maintained unless the disease progresses rapidly or severe intolerance is manifested.

Active ingredient

Recombinant interferon alfa-2b is a sterile, stable, formulation of highly purified interferon alfa-2b produced by recombinant DNA techniques. Interferons exert their cellular activities by binding to specific membrane receptors on the cell surface. Recombinant interferon alfa-2b has exhibited antiproliferative effects in studies employing both animal and human cell culture systems as well as human tumour xenografts in animals. It has demonstrated significant immunomodulatory activity in vitro.

Read more about Interferon, alfa-2b

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner